NSI Pulsed Electromagnetic Field (PEMF) Biomarker Study
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 9/2/2018 |
| Start Date: | September 1, 2018 |
| End Date: | November 1, 2019 |
| Contact: | Edwin M Nemoto, PhD |
| Email: | Enemoto@salud.unm.edu |
| Phone: | 505-272-5990 |
14-113 Nemoto: NSI PEMF Biomarker Study
Pulsed Electromagnetic Field (PEMF) Reduction of CSF and Serum Biomarkers After Traumatic
Brain Injury (TBI).
The primary objective of this pilot study is to determine whether PEMF treatment (PEMF+)
reduces the magnitude and duration of the increase in CSF and blood biomarkers after
traumatic brain injury (TBI) compared to a PEMF untreated (PEMF-) group. Values in both
groups are compared to uninjured brain CSF and blood biomarker levels obtained from
hydrocephalus patients undergoing ventriculo-peritoneal shunt placement. A secondary
objective of this pilot study is to determine whether PEMF treatment improves the physiologic
status of the brain as evaluated by brain tissue monitors of thermal dilution cerebral blood
flow (CBF), intracranial pressure (ICP), and tissue PO2 (PbtO2). Improved physiologic status
would be reflected by increased CBF, PbtO2, and reduced ICP. Improved physiologic status may
also be inferred from derived variables reflecting improved cerebrovascular and intracranial
pressure autoregulation.
A tertiary objective of this pilot study is to obtain preliminary data on the relationship
between the time course and magnitude of post-TBI CSF and blood biomarker levels as they
relate to three month outcome by Glasgow outcome score extended (GOSE) and modified Rankin
Score (mRS).
Brain Injury (TBI).
The primary objective of this pilot study is to determine whether PEMF treatment (PEMF+)
reduces the magnitude and duration of the increase in CSF and blood biomarkers after
traumatic brain injury (TBI) compared to a PEMF untreated (PEMF-) group. Values in both
groups are compared to uninjured brain CSF and blood biomarker levels obtained from
hydrocephalus patients undergoing ventriculo-peritoneal shunt placement. A secondary
objective of this pilot study is to determine whether PEMF treatment improves the physiologic
status of the brain as evaluated by brain tissue monitors of thermal dilution cerebral blood
flow (CBF), intracranial pressure (ICP), and tissue PO2 (PbtO2). Improved physiologic status
would be reflected by increased CBF, PbtO2, and reduced ICP. Improved physiologic status may
also be inferred from derived variables reflecting improved cerebrovascular and intracranial
pressure autoregulation.
A tertiary objective of this pilot study is to obtain preliminary data on the relationship
between the time course and magnitude of post-TBI CSF and blood biomarker levels as they
relate to three month outcome by Glasgow outcome score extended (GOSE) and modified Rankin
Score (mRS).
Investigators will enroll a total of 45 subjects, 30 after TBI and 15 patients with
hydrocephalus having ventriculo-peritoneal shunts inserted. It is anticipated that in order
to enroll 30 TBI participants investigators will need to screen approximately 50 subjects;
and for the patients undergoing ventriculo-peritoneal shunt placement we will need to screen
30 patients in order to enroll 15. Of the 30 TBI patients, 15 will have PEMF+ and 15 will
have PEMF-. PEMF+ means that the device will be in place and will be on, PEMF- means that the
device will be in place but will not be turned on.
The study will be double blinded. The honest broker (HB) Dr. Amal Alchbli, will not be
involved in the study except to turn on the PEMF device with the indicator light showing when
the PEMF device is on , will be hidden from view by tape. The HB will keep a list of the
patients treated with PEMF+ or not PEMF- along with their MRN# coded and the start and end
times of PEMF treatment during their stay in the NSI. The nurses in the unit will be asked to
indicate on the CNS monitor when the PEMF applicators are on or off the patient.
The subjects will participate in this study for up to one week while in the Neuroscience
Intensive Care Unit (NSI). There will also be follow up on secondary clinical outcome
measures at discharge, one and three months post discharge. The one and three month follow
ups will be conducted over the phone.
The duration of enrollment is expected to be two years. The estimated date for the
investigators to complete this study (complete primary analyses) is 3.0 years.
The estimated time for data retention is 5 years.
Table 1: Clinical evaluations throughout the study in both TBI and CVA patients.
Scored on TBI patients Admission Impact Score Daily for up to 7 days GCS Discharge GCS One
and three months GOSE, DRS, mRS
hydrocephalus having ventriculo-peritoneal shunts inserted. It is anticipated that in order
to enroll 30 TBI participants investigators will need to screen approximately 50 subjects;
and for the patients undergoing ventriculo-peritoneal shunt placement we will need to screen
30 patients in order to enroll 15. Of the 30 TBI patients, 15 will have PEMF+ and 15 will
have PEMF-. PEMF+ means that the device will be in place and will be on, PEMF- means that the
device will be in place but will not be turned on.
The study will be double blinded. The honest broker (HB) Dr. Amal Alchbli, will not be
involved in the study except to turn on the PEMF device with the indicator light showing when
the PEMF device is on , will be hidden from view by tape. The HB will keep a list of the
patients treated with PEMF+ or not PEMF- along with their MRN# coded and the start and end
times of PEMF treatment during their stay in the NSI. The nurses in the unit will be asked to
indicate on the CNS monitor when the PEMF applicators are on or off the patient.
The subjects will participate in this study for up to one week while in the Neuroscience
Intensive Care Unit (NSI). There will also be follow up on secondary clinical outcome
measures at discharge, one and three months post discharge. The one and three month follow
ups will be conducted over the phone.
The duration of enrollment is expected to be two years. The estimated date for the
investigators to complete this study (complete primary analyses) is 3.0 years.
The estimated time for data retention is 5 years.
Table 1: Clinical evaluations throughout the study in both TBI and CVA patients.
Scored on TBI patients Admission Impact Score Daily for up to 7 days GCS Discharge GCS One
and three months GOSE, DRS, mRS
Inclusion Criteria:
Age > 18 years old GCS <9 Male or Female Placement of multimodality monitoring Hummingbird
device or an External Ventricular Drain as part of clinical treatment/care.
Multimodality monitoring as part of clinical treatment/care
Exclusion Criteria:
Pregnant Vulnerable population: Prisoners, No legally authorized representative (LAR).
Patients with implanted metallic leads. Implants include cardiac pacemakers/defibrillators,
cochlear implants, bone growth stimulators, deep brain stimulators, spinal cord stimulators
and other nerve stimulators.
Patients without multimodality monitoring or an EVD/Hummingbird Device
We found this trial at
1
site
University of New Mexico Founded in 1889 as New Mexico’s flagship institution, the University of...
Click here to add this to my saved trials
